23-Dec-2024
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Benzinga (Mon, 23-Dec 1:20 PM ET)
GSK COVID antiviral authorization for sotrovimab revoked by FDA
Seeking Alpha News (Mon, 23-Dec 12:55 PM ET)
GlaxoSmithKline (GSK) Gets a Hold from Barclays
TipRanks (Fri, 20-Dec 1:15 PM ET)
GSK reports mixed results from Phase 3 ovarian cancer study
Seeking Alpha News (Fri, 20-Dec 10:15 AM ET)
GSK Hits Key Milestone in Ovarian Cancer Trial
TipRanks (Fri, 20-Dec 5:16 AM ET)
Benzinga (Thu, 19-Dec 1:38 PM ET)
GlaxoSmithKline (GSK) Gets a Hold from Goldman Sachs
TipRanks (Thu, 19-Dec 11:55 AM ET)
Globe Newswire (Wed, 18-Dec 8:45 AM ET)
Business Wire (Mon, 9-Dec 1:38 PM ET)
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Globe Newswire (Mon, 18-Nov 7:30 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of December 23, 2024, GSK stock price climbed to $34.06 with 3,029,790 million shares trading.
GSK has a beta of 0.36, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.05 to the broad based SPY ETF.
GSK has a market cap of $69.45 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $10 billion in Revenue and $1.29 earnings per share. This fell short of revenue expectation by $-362 million and exceeded earnings estimates by $.06.
In the last 3 years, GSK traded as high as $46.97 and as low as $28.47.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): FVD, GCOW, PPH, AVDE, FENI.
GSK has underperformed the market in the last year with a return of -1.6%, while the SPY ETF gained +28.5%. In the last 3 month period, GSK fell short of the market, returning -15.6%, while SPY returned +5.0%. However, in the most recent 2 weeks GSK has outperformed the stock market by returning -1.5%, while SPY returned -1.8%.
GSK support price is $33.19 and resistance is $34.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.